Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06159439 |
Other study ID # |
23018 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 2, 2024 |
Est. completion date |
February 2, 2025 |
Study information
Verified date |
November 2023 |
Source |
University of Nottingham |
Contact |
Kerry Horne, BMBCh |
Phone |
07469037422 |
Email |
kerry.horne[@]nottingham.ac.uk |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Blood flow to the kidneys is important in the development of kidney diseases. Currently we do
not have ways of measuring and monitoring kidney blood flow for patients in real-time. This
is a major barrier to investigation and management of acute kidney injury (AKI) and chronic
kidney disease (CKD).
Kidney blood flow can be reliably measured using a specialised type of MRI scan, but this is
expensive and difficult to do in people who are unwell. Contrast-enhanced ultrasound (CEUS)
is a new technique, which uses a contrast containing microbubbles to measure blood flow. The
benefits of this method are that it is relatively inexpensive, the contrast agents are not
kidney-damaging and it can be done at the bedside.
We want to compare contrast enhanced ultrasound against the current best-measure of kidney
blood flow, to see if it is giving accurate information about kidney blood flow. We will do
this by doing both MRI and contrast enhanced ultrasound scans in people with chronic kidney
disease and comparing the results.
Description:
Renal perfusion, the delivery of oxygenated blood to kidney tissues, is relevant to a number
of acute and chronic kidney diseases. Despite this, we do not have methods in current
clinical practice to measure renal perfusion and monitor the response to supportive
treatments in real time. This is a major barrier to investigation and management of acute
kidney injury (AKI) and chronic kidney disease (CKD).
The current non-invasive gold standard technique for renal perfusion measurement is
arterial-spin labelling magnetic resonance imaging (ASL-MRI), which has been validated
against other measures of perfusion, including contrast agent-based methods. However, MRI has
limitations including high cost, and logistical barriers. Therefore, validation of a bed-side
measurement tool for renal perfusion would be of significant clinical importance.
This proposal aims to validate CEUS renal cortical perfusion measurement by comparison with
quantifiable ASL-MRI parameters of renal microvascular perfusion in individuals with CKD.
TRIAL REGIMEN
All interventions outlined below are for the purposes of research, not usual care.
Study day:
All participants will attend fasted for preceding 2 hours. Demographic details and medical
history will be recorded. The patient's concomitant medications which form part of their
usual care will be recorded. These will not be adjusted.
Results of blood and urine tests that are collected as part of clinical care will be
recorded.
Participants will undergo two scanning sessions, the first using renal MRI at the Sir Peter
Mansfield Imaging Centre (SPMIC) to provide a quantitative measure of renal perfusion, and
the second to provide the comparator measure of renal perfusion using CEUS performed at Royal
Derby Hospital.
Outcomes:
MRI derived perfusion variables: peak time, and peak signal intensity (SI) will be obtained
from time intensity curves.
Mean flow velocity (cm/s), cross-sectional area of the lumen (mm2), and hence bulk renal
blood flow (ml/s)
CEUS derived perfusion parameters: acoustic index (AU); mean transit time (seconds);
perfusion index, which is the ratio of AI to mTT; and wash-in rate (seconds)